Evidence map›Paper›PMID 41299238›Full record

ArticleThe journal of headache and pain2025

Clinical characteristics and social burden of menstrual migraine in Japan: an online-based cross-sectional questionnaire study.

Tsubasa Takizawa, Keiko Ihara, Reiko Yoshikawa, Kanae Togo, Takahiro Kitano, Masahiro Iijima

Abstract read
In one paragraph

Article in The journal of headache and pain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tsubasa TakizawaDepartment of Neurology, Keio University School of Medicine, Tokyo, Japan.
Keiko IharaDepartment of Neurology, Keio University School of Medicine, Tokyo, Japan.
Reiko YoshikawaInternal Medicine/Hospital/Antiviral Medical Affairs, Pfizer Japan Inc., Shinjuku Bunka Quint Building, Tokyo, 3-22-7 Yoyogi, Shibuya-ku, 151-8589, Japan. reiko.yoshikawa@pfizer.com.ORCID http://orcid.org/0000-0003-2341-3601
Kanae TogoAccess & Value, Pfizer Japan Inc., Tokyo, Japan.
Takahiro KitanoAccess & Value, Pfizer Japan Inc., Tokyo, Japan.
Masahiro IijimaInternal Medicine/Hospital/Antiviral Medical Affairs, Pfizer Japan Inc., Shinjuku Bunka Quint Building, Tokyo, 3-22-7 Yoyogi, Shibuya-ku, 151-8589, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMenstrual migraine (MM) is a distinct and burdensome subtype of migraine; however, comprehensive data on its clinical and social impact among Japanese females remain limited. Therefore, we aimed to clarify the clinical characteristics and social burden of MM in Japan.

methodsA cross-sectional, population-based web survey was conducted among Japanese females (≥ 18 years) with regular menstruation who were diagnosed with migraine. Participants were classified into MM and non-MM groups. Clinical parameters assessed between MM and non-MM included pain intensity, pain duration, and headache frequency during the perimenstrual period (-2 days to + 2 days of menstruation onset). Social burden was evaluated using the Migraine Disability Assessment (MIDAS), Migraine Interictal Burden Scale (MIBS-4), Migraine-Specific Quality of Life Questionnaire (MSQ), and Work Productivity and Activity Impairment for Migraine (WPAI-M). These were compared between MM and non-MM, adjusting for potential confounders through inverse probability of treatment weighting using propensity scores.

resultsOf 266,392 screened patients, 4,592 were included in MM and 5,174 in non-MM. The mean age was 36.8 ± 8.0 years in MM and 35.5 ± 8.3 years in non-MM. MM patients experienced higher pain intensity and longer pain duration than non-MM during both perimenstrual and non-perimenstrual periods (perimenstrual periods: -2 days to + 1 day of menstruation onset: all p < 0.001 for both, +2 days of menstruation onset: intensity, p = 0.003, duration, p = 0.046; non-perimenstrual period: intensity, p < 0.001, duration, p = 0.005). MM exhibited higher MIDAS and MIBS-4 scores (both p < 0.001) and lower MSQ scores (restriction, interference, emotion: all p < 0.001), indicating greater disability and reduced quality of life. Among WPAI-M scores, presenteeism, overall work and activity impairment, were also higher in MM vs non-MM (all p < 0.001). MM demonstrated increased usage (MM: 54.0% [1,088/2,015]; non-MM: 24.0% [169/705]) and broader type of medications (MM: 13.2% [265/2,015]; non-MM: 7.1% [50/705]) during the perimenstrual period, particularly non-steroidal anti-inflammatory drugs (MM: 51.4% [801/1,557]; non-MM: 45.4% [636/1,402]).

conclusionsThis study highlights the significant burden of MM, demonstrating increased pain intensity, longer pain duration and higher headache frequency during perimenstrual period, accompanied by a concurrent increase in social burden compared to non-MM. These findings underscore the impact of clinical severity and social burden of MM in Japanese females.

Indexed as

Cost of IllnessMenstruationMenstruation DisturbancesMigraine DisordersQuality of LifeAdultCross-Sectional StudiesFemaleHumansInternetJapanMiddle AgedSurveys and QuestionnairesYoung AdultCross-sectional studyMenstrually related migraineMenstrual migraineReal-world evidenceSocial burden

Identifiers

PMID41299238
PMCPMC12659224

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.